drugset / Trial / NCT03856853
Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease
Phase 3
Unknown
144 enrolled
Beijing Continent Pharmaceutical Co, Ltd.
GNI-EPS Pharmaceuticals, Inc. (GNI Group) · collabShanghai Genomics, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Timeline
- Start
- 2018-06-15
- Primary completion
- 2021-02-10
- Completion
- 2021-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirfenidone | Small molecule | — | — |